Recursion Pharmaceuticals (NASDAQ: RXRX), a $3.03 billion market cap biotech company, reported a larger-than-expected loss for Q4 2024, with an EPS of -0.53 compared to the forecasted -0.41. The ...
Recursion Pharmaceuticals reported its second-quarter 2025 earnings with revenue significantly surpassing expectations, while earnings per share (EPS) fell short. The company posted an actual EPS of ...
Earnings call Recursion reported a transformative quarter marked by its initial clinical proof of concept for FAP, a 35% YoY reduction in pro forma operating expenses, and $754 million in year-end ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The recent earnings call for Recursion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results